Coatings with crystallized active agent(s) and methods
View Patent ↗Coatings with crystallized active agent(s) and related methods are disclosed. One method includes selecting a solvent and a polymer, selecting a concentration of an active agent of at least a certain amount of saturation, forming a coating composition having the selected concentration of the active agent, and applying the coating composition to the medical device. Also disclosed is an elution control coating which includes an active agent that is at least about 80% crystallized within one week of being disposed on a medical device. One method enhances the formation of active agent crystals within a coating layer by adjusting the concentration of the active agent in the coating solution to reach some percentage of the active agent saturation point. Another method includes increasing the rate of active agent nucleation within the coating.
1. An elution control coating disposed on a medical device, the elution control coating comprising: a hydrophobic polymer, and an active agent comprising a steroid, wherein the active agent is at least 80% crystallized within one week of being disposed on the medical device.
2. The elution control coating of claim 1 , wherein the active agent is at least 90% crystallized within one week of being disposed on the medical device.
3. The elution control coating of claim 1 , wherein the active agent is at least 95% crystallized within one week of being disposed on the medical device.
4. The elution control coating of claim 1 , wherein the active agent is at least 95% crystallized within one day of being disposed on the medical device.
5. The elution control coating of claim 1 , the active agent comprising dexamethasone.
6. The elution control coating of claim 1 , the polymer comprises a first polymer component comprising at least one poly(alkyl)(meth)acrylate and a second polymer component comprising poly(ethylene-co-vinyl acetate).
7. The elution control coating of claim 1 , the polymer comprises a first polymer component comprising at least one poly(alkyl)(meth)acrylate and a second polymer component comprising poly(ethylene-co-vinyl acetate), wherein the second polymer component is selected from the group consisting of poly(ethylene-co-vinyl acetate) polymers having vinyl acetate concentrations of between about 10% and about 50% by weight.